2 weeks ago it set a new high at $49.09 and the next morning it was $4.50 lower, more or less.
It is a low float stock and subject to wild swings.
I just try to watch the trend..... which is good; increasingly upwards.
I feel as though (just as we saw recently with Gilead) that the strong hands are trying to shake out the little investors before an upswing.
Gilead has a great treatment and is a great program. It's crazy to sell at a low, IMHO. And yet many people did just that.
Today's ENTA share price drop means little to me in the actual value of the shares. The share price trend and the recent upgrade tells me to stay put.
The fundamentals of this stock have remained virtually unchanged in the year I have owned it; but the share price as been all over the place.
Yes, I agree that the upcoming approval indications will be important (12 week versus 24 week and for what indications)
This was a somewhat larger deal in the recent Gilead approvals;
8 week off label but left up to the doctor/viral load
24 weeks for one sub group.
When the Abbvie- ENTA 3D program is approved we will see some price swings in share price.
What will remain unknown, is the response by the payors.
For me, Gilead has a great program; it's fantastic!!!
But it is another question; what % of the sub-groups will get approval for treatments in the 3D program? The payment approval distribution will not the same as the HCV infected aggregate.
In my experience, I went untreated for 10 years with no issues; virtually no medical expense. The sick ones though..... they are 200x more expensive than the well ones.
IMHO, the sickest are going first, meaning that the sub-group where the 3-D program is strongest compared to Gilead/Harvoni TX.
This will be the largest unknown remaining when the Abbvie Program is approved, and pricing is listed.
I have little trading experience myself, and I sold at Gilead's Sovaldi approval. (either smart or lucky)
BUT....there is a potential for a buyout with this company, so it could pull an IDIX some morning when we wake up and look at share price. One could make some money selling at the news, to lose far more money while awaiting a lower buy in point.
At any given moment.... the value is not priced in, IMHO.
Recent ENTA News
- Enanta Pharmaceuticals to Participate in Investor Conferences in September • Business Wire • 09/03/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 09:24:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:10 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Business Wire • 08/05/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 09:29:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM